A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer

A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer

Edward B Garon,1,2 Jeffrey D Neidhart,3 Nashat Y Gabrail,4 Moacyr R de Oliveira,5 Jai Balkissoon,6 Fairooz Kabbinavar1,2 1Department of Medicine, 2Department of Hematology and Oncology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, 3San Juan Oncology Asso...

Full description

Bibliographic Details
Main Authors: Garon EB, Neidhart JD, Gabrail NY, de Oliveira MR, Balkissoon J, Kabbinavar F
Format: Article
Language:English
Published: Dove Medical Press 2016-11-01
Series:OncoTargets and Therapy
Subjects:
CA4P
bevacizumab
paclitaxel
carboplatin
NSCLC
Online Access:https://www.dovepress.com/a-randomized-phase-ii-trial-of-the-tumor-vascular-disrupting-agent-ca4-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/a-randomized-phase-ii-trial-of-the-tumor-vascular-disrupting-agent-ca4-peer-reviewed-article-OTT

Similar Items